Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients

View Full Paper
Ask AI
Bookmark
Share

Authors

GMGema MirallesJBJuan BerguaFCFerran Vall‐Llovera Calmet

Discussion

Loading...

Member takes

Overview

Multicenter cohort study shows gilteritinib offers treatment potential for relapsed FLT3-mutated AML, despite toxicity challenges.

Key Points

  • To assess the effectiveness of gilteritinib in relapsed/refractory FLT3-mutated acute myeloid leukemia beyond second-line therapy.
  • Retrospective cohort study of 171 patients with FLT3-mutated AML.
  • Examination of overall survival and overall response rate following gilteritinib treatment.
  • Data collected from multiple centers in Europe.
  • Median overall survival was 7.1 months, with significant variation based on treatment prior exposure.
  • Overall response rate was 47%; 28% achieved composite complete remission.
  • Common treatment discontinuations were due to refractory disease and toxicity.

Cite This Study

Miralles et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3aahttps://doi.org/10.1182/blood-2025-1662
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience2025 · 7 citations
  2. 2Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 ( <scp>FLT3</scp> )‐mutated acute myeloid leukaemia patients: A multicentre real‐world study2026
  3. 3Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations2026
  4. 4A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study2025
  5. 5Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation2025 · 2 citations